Anebulo

Anebulo Pharmaceuticals Shares Q2 FY2026 Financial Performance and Corporate Highlights

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates Anebulo Pharmaceuticals, Inc. a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the…

Read MoreAnebulo Pharmaceuticals Shares Q2 FY2026 Financial Performance and Corporate Highlights
Therapeutics

Encora Therapeutics Wins FDA Clearance for Encora X1™ Breakthrough Tremor Device

Encora Therapeutics Receives FDA 510(k) Clearance for Encora X1™, a Breakthrough Wearable Device for Essential Tremor Encora Therapeutics, a leader in non-invasive neuromodulation technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the…

Read MoreEncora Therapeutics Wins FDA Clearance for Encora X1™ Breakthrough Tremor Device
KalVista

KalVista Pharmaceuticals Showcases EKTERLY® Data at AAAAI 2026 Annual Meeting

KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals, Inc. today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology…

Read MoreKalVista Pharmaceuticals Showcases EKTERLY® Data at AAAAI 2026 Annual Meeting
Zeon Corporation

Zeon Corporation Makes Strategic Investment in Chemify to Accelerate Automated Molecular Design

Zeon Corporation Makes Strategic Investment in Chemify to Accelerate Digital Chemistry Innovation and Drive Development of New Materials Through State-of-the-Art Automated Molecular Design and Synthesis Zeon Corporation (Zeon; head office: Chiyoda-ku, Tokyo; President and CEO: Tetsuya Toyoshima), through its venture…

Read MoreZeon Corporation Makes Strategic Investment in Chemify to Accelerate Automated Molecular Design
iProov

iProov Dynamic Liveness Sets Industry First with Top Injection Attack Detection Certifications

iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN/TS 18099 High and Ingenium Level 4 for Injection Attack Detection iProov, the world’s leading provider of science-based biometric identity verification solutions, today announced that its Dynamic Liveness technology…

Read MoreiProov Dynamic Liveness Sets Industry First with Top Injection Attack Detection Certifications
Galderma

Galderma Introduces First-of-Its-Kind “We Are All Sculptra” Campaign Showcasing Treatment Benefits

We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties Galderma the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine…

Read MoreGalderma Introduces First-of-Its-Kind “We Are All Sculptra” Campaign Showcasing Treatment Benefits
SkySense

WellSky Expands SkySense AI™ to Long-Term Care and Skilled Nursing Facilities

WellSky SkySense AI™ Expands to Long-Term Care and Skilled Nursing Facilities WellSky® a global health and community care technology and services company, today announced that the WellSky Long-Term Care solution, powered by SkySense AI, is now available, extending artificial intelligence (AI) capabilities…

Read MoreWellSky Expands SkySense AI™ to Long-Term Care and Skilled Nursing Facilities
Head & Shoulders

Head & Shoulders Launches BARE Itchy Scalp Relief Serum to Prevent Recurring Itch and Flakes Between Washes

Head & Shoulders Launches BARE Itchy Scalp Relief Serum to Prevent Recurring Itch and Flakes Between Washes Head & Shoulders, the world’s #1 anti-dandruff shampoo, introduces Head & Shoulders BARE Itchy Scalp Relief Serum, a breakthrough scalp care solution designed to…

Read MoreHead & Shoulders Launches BARE Itchy Scalp Relief Serum to Prevent Recurring Itch and Flakes Between Washes
AstraZeneca

AstraZeneca Awards $3.4 Million to Expand Healthcare Access Programs Across the U.S.

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US AstraZeneca has proudly awarded $3.4 million to nonprofit organizations in the US through its Accelerate Change Together (ACT) on Health Equity initiative. This effort aims to support programming…

Read MoreAstraZeneca Awards $3.4 Million to Expand Healthcare Access Programs Across the U.S.